Kratom Advocates Urge Industry Compliance, FDA And DEA Compassion

Now that FDA has completed its evaluations of two compounds in kratom – mitragynine and 7-hydroxymitragynine – that DEA has proposed to schedule as controlled substances, researchers who attest to the ingredient's safety and its value in helping opioid abusers through withdrawal or as a natural pain reliever or mood enhancer say time could be running short to convince federal officials against ending consumer access to kratom products due to fear that the ingredient is an opioid.

FDA should regulate kratom as a dietary ingredient rather than the health threat the agency claims it is, not only due to its history of safe use similar to other botanicals but also because like other supplement ingredients, some products labeled as kratom are adulterated and should be removed from the market, experts say.

Now that FDA has completed its evaluations of two compounds in kratom – mitragynine and 7-hydroxymitragynine – that the Drug Enforcement Administration has proposed to schedule as controlled substances, researchers who attest to the ingredient's safety and its value in helping opioid abusers through withdrawal or as a natural pain reliever or mood enhancer say time could be running

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America